OraSure Technologies (NASDAQ:OSUR) has earned a consensus recommendation of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $21.50.
Several research analysts have weighed in on OSUR shares. BidaskClub upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. ValuEngine upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research report on Friday, February 9th. Finally, Canaccord Genuity restated a “buy” rating and set a $24.00 target price on shares of OraSure Technologies in a research report on Friday, February 2nd.
NASDAQ OSUR remained flat at $$17.76 during trading hours on Wednesday. 204,737 shares of the company traded hands, compared to its average volume of 629,390. The stock has a market capitalization of $1,063.85, a PE ratio of 34.84, a P/E/G ratio of 4.86 and a beta of 1.65. OraSure Technologies has a 52-week low of $12.41 and a 52-week high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The firm had revenue of $52.00 million during the quarter, compared to analysts’ expectations of $50.20 million. During the same period in the prior year, the company posted $0.13 earnings per share. The firm’s revenue for the quarter was up 46.5% on a year-over-year basis. analysts expect that OraSure Technologies will post 0.29 EPS for the current year.
In other OraSure Technologies news, Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $17.97, for a total transaction of $419,294.01. Following the transaction, the director now directly owns 59,749 shares in the company, valued at $1,073,689.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Brian Smith sold 20,000 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $17.97, for a total transaction of $359,400.00. Following the transaction, the executive vice president now owns 28,075 shares in the company, valued at $504,507.75. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in OSUR. Schwab Charles Investment Management Inc. grew its position in shares of OraSure Technologies by 16.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 262,429 shares of the medical instruments supplier’s stock valued at $5,905,000 after purchasing an additional 36,436 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of OraSure Technologies in the third quarter valued at approximately $1,323,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of OraSure Technologies in the third quarter valued at approximately $186,000. McCollum Christoferson Group LLC acquired a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $2,043,000. Finally, Fisher Asset Management LLC grew its position in shares of OraSure Technologies by 12.8% in the fourth quarter. Fisher Asset Management LLC now owns 627,828 shares of the medical instruments supplier’s stock valued at $11,841,000 after purchasing an additional 71,373 shares during the last quarter. Institutional investors and hedge funds own 92.86% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.